Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Protalix BioTherapeutics reports on taliglucerase alfa switchover trial

Nov. 3, 2010

New modulators of G protein-coupled receptors disclosed

Nov. 3, 2010

GSK and Amicus to develop Amigal for Fabry's disease

Nov. 2, 2010

FDA requests additional information from VIVUS regarding Qnexa NDA

Nov. 2, 2010

Febuxostat launched for hyperuricemia in Canada

Oct. 29, 2010

Nippon Chemiphar claims new PPAR-delta receptor agonists

Oct. 29, 2010

Validation of DM-199 shown by significantly increasing insulin sensitivity

Oct. 29, 2010

Eisai discontinues development of antiobesity drug KES-524

Oct. 29, 2010

Nascobal to be commercialized outside U.S. for vitamin B12 deficiency

Oct. 28, 2010

PTC Therapeutics begins phase II ataluren trial in nmMMA

Oct. 28, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....